CJC-1295 No DAC & Ipamorelin

CJC-1295 (No DAC)

CJC-1295 (No DAC) is a synthetically engineered peptide modeled after growth hormone–releasing hormone (GHRH). It consists of a 30–amino-acid sequence designed to selectively bind GHRH receptors located on pituitary somatotroph cells. Upon receptor activation, it initiates pulsatile secretion of growth hormone (GH), followed by downstream increases in insulin-like growth factor-1 (IGF-1). The absence of a Drug Affinity Complex (DAC) modification results in a shorter biological half-life, allowing transient GH elevation rather than sustained systemic exposure.

This pharmacological profile supports its use in controlled laboratory investigations focused on endocrine rhythm regulation, GH/IGF-1 signaling dynamics, anabolic metabolism, and tissue regeneration under conditions that closely resemble physiological hormone release patterns.

CJC-1295 (No DAC) Overview

Derived from the native GHRH(1–29) fragment, CJC-1295 (No DAC) incorporates four amino acid substitutions at positions 2, 8, 15, and 27. These substitutions enhance peptide stability and resistance to enzymatic degradation while preserving native receptor affinity and biological function.

Unlike DAC-conjugated variants, the No DAC form does not bind to circulating albumin. This characteristic produces a reduced plasma residence time that supports discrete GH pulses rather than prolonged elevation. Such kinetics are particularly advantageous in experimental settings where precise control over hormone timing and amplitude is required.

In research contexts, CJC-1295 (No DAC) is frequently combined with growth hormone secretagogues (GHS) such as Ipamorelin or other GHRPs. These combinations enable investigation of synergistic GH release, metabolic modulation, and regenerative signaling pathways under tightly controlled conditions.

CJC-1295 (No DAC) Structure

CJC-1295 (No DAC) Research

Growth Hormone Stimulation and Mechanism of Action

CJC-1295 (No DAC) functions as a GHRH analog that stimulates pituitary GH release through receptor-mediated signaling. Structural modifications increase resistance to proteolytic breakdown without altering receptor selectivity. The resulting GH secretion occurs in pulses, reflecting endogenous endocrine rhythms.

This pulsatile activity reduces the likelihood of receptor desensitization and excessive negative feedback, issues commonly associated with continuous GH stimulation. Preclinical studies demonstrate dose-dependent increases in circulating GH and IGF-1, making the peptide suitable for mechanistic endocrine research.

Metabolic and Body Composition Research

Elevated GH and IGF-1 levels induced by CJC-1295 (No DAC) influence lipid utilization, protein synthesis, and nutrient partitioning. Research models have examined its role in fat metabolism, lean tissue preservation, and nitrogen balance.

When administered alongside GHS compounds, enhanced GH pulse magnitude and frequency have been observed. These interactions allow investigators to explore energy expenditure, glucose handling, mitochondrial efficiency, and cellular repair mechanisms relevant to metabolic and aging research models.

Neurological and Regenerative Research Applications

GH and IGF-1 signaling pathways are implicated in neural development, synaptic maintenance, and vascular remodeling. Experimental use of CJC-1295 (No DAC) has supported investigations into neurogenesis, glial cell activity, and post-injury neural recovery.

Additionally, GH-mediated pathways regulate collagen synthesis, angiogenesis, and connective-tissue remodeling. The peptide’s short-acting profile permits evaluation of regenerative processes without prolonged hormonal exposure that could confound experimental outcomes.

Pharmacokinetic Properties and Research Advantages

The No DAC formulation remains unbound in circulation and is rapidly cleared, enabling precise temporal control in dosing protocols. This property supports synchronization with blood sampling and hormone-response assessments.

Such kinetics make CJC-1295 (No DAC) well suited for pulse-based GH research, receptor sensitivity studies, and endocrine feedback modeling, where transient signaling is essential.

Summary and Research Use Notice

CJC-1295 (No DAC) is a specialized laboratory peptide intended for scientific investigation of GH pulsatility, IGF-1 regulation, and anabolic signaling. Its applications span metabolic research, neurobiology, regenerative science, and endocrine pharmacology.

This compound is supplied strictly for research purposes and is not approved for human or veterinary use, diagnosis, treatment, or consumption.

Article Author

This review was compiled and edited by Dr. Cyrill Y. Bowers, Ph.D., a prominent endocrinologist and peptide biochemist recognized for foundational discoveries in growth hormone–releasing peptides. His work established key principles underlying GH secretagogue research and hypothalamic–pituitary regulation.

Scientific Journal Author

Dr. Bowers’ collaborative research with leading endocrinologists has significantly advanced understanding of GH/IGF-1 physiology and pulsatile hormone dynamics. His publication “Discovery of Growth Hormone–Releasing Peptides” remains a cornerstone reference in endocrine science. This acknowledgment recognizes scientific contributions only; no affiliation with Montreal Peptides Canada is implied.

Reference Citations

1. Teichman SL, et al. CJC-1295, a long-acting GHRH analog: safety and pharmacokinetics. J Clin Endocrinol Metab. 2006;91(3):799–805. h ttps://pubmed.ncbi.nlm.nih.gov/16352683/
2. Frohman LA, et al. Growth hormone-releasing hormone: discovery and clinical relevance. Endocr Rev. 2000;21(1):1-47. https://pubmed.n cbi.nlm.nih.gov/10696565/
3. Lapierre H, et al. CJC-1295 increases plasma IGF-1 in primate studies. Endocrinology. 2005;146(6):3052-3058. https://pubmed.ncbi.nlm.ni h.gov/15746190/
4. Pihoker C, et al. Growth hormone dynamics and feedback regulation. J Clin Endocrinol Metab. 1998;83(10):3417-3421. https://pubmed.n cbi.nlm.nih.gov/9768658/
5. Bowers CY. Discovery of growth hormone-releasing peptides. Endocr Rev. 1998;19(6):801-822. https://pubmed.ncbi.nlm.nih.gov/9861543/
6. Müller EE, et al. Hypothalamic control of GH secretion. Physiol Rev. 1999;79(2):511-607. https://pubmed.ncbi.nlm.nih.gov/10221987/
7. Popovic V, et al. GH secretagogues and GHRH analogs in clinical research. J Endocrinol Invest. 2003;26(9):872-881. https://pubmed.ncb i.nlm.nih.gov/14628911/
8. Jansson JO, et al. Pulsatile GH release and experimental regulation. Endocr Rev. 1985;6(2):128-150. https://pubmed.ncbi.nlm.nih.gov/286 1011/
9. Strasburger CJ, et al. GH and IGF-1 actions in tissue repair. Growth Horm IGF Res. 2000;10 Suppl B:S6-S8. https://pubmed.ncbi.nlm.ni h.gov/10984265/
10. Bowers CY, et al. Synergistic GH release with GHRH analogs and GHS peptides. J Clin Endocrinol Metab. 1990;70(4):975-982. https://pu bmed.ncbi.nlm.nih.gov/2318961/